Search

Displaying results 1901 - 1910 of 10000 in total
  1. Drug

    Icatibant

    go.drugbank.com/drugs/DB06196
    ApprovedInvestigational

    [A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema. … Icatibant is a synthetic decapeptide with 5 nonproteinogenic amino acid antagonist targeting the B<sub>2</sub> receptors with a similar affinity to bradykinin.

    Products: İKTU 30 MG/3 ML ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, FIRAZYR 30 MG/3 ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET
  2. Drug

    Bexarotene

    go.drugbank.com/drugs/DB00307
    ApprovedInvestigational

    Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.

    Synonyms: 4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid, 4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acidCategories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 Substrates
  3. Target

    High mobility group protein HMG-I/HMG-Y

    go.drugbank.com/bio_entities/BE0012648
    TargetHumans

    HMG-I/Y bind preferentially to the minor groove of A+T rich regions in double-stranded DNA. … They are also involved in the transcription regulation of genes containing, or in close proximity to A+T-rich regions

    Polypeptides: High mobility group protein HMG-I/HMG-YSynonyms: HMG-I(Y)
  4. Drug

    Cloperastine

    go.drugbank.com/drugs/DB09002
    Investigational

    Cloperastine is a cough suppressant that acts on the central nervous system.

    Categories: Heterocyclic Compounds, 1-RingProducts: FENTUS 708 MG/100 ML ORAL SÜSPANSİYON, 200 ML, FENTUS 708 MG/100 ML ORAL SÜSPANSİYON, 100 ML
  5. Drug

    Cholic Acid

    go.drugbank.com/drugs/DB02659
    ApprovedInvestigational

    [PubChem] Cholic acid, formulated as Cholbam capsules, is approved by the United States Food and Drug Administration as a treatment for children and adults with bile acid synthesis disorders due to single … A major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.

    Categories: P-glycoprotein inducersProducts: ORPHACOL ® 250 MG, ORPHACOL®50 MG
  6. Drug

    Tenofovir alafenamide

    go.drugbank.com/drugs/DB09299
    ApprovedInvestigational

    Tenofovir alafenamide is a novel [tenofovir] prodrug developed in order to improve renal safety when compared to the counterpart [tenofovir disoproxil]. … [A178219] It has been reported to produce a large antiviral efficacy at doses ten times lower than tenofovir disoproxil.

    Mixtures: Descovy® (emtricitabine 200 mg/ tenofovir alafenamide 10 mg) film-coated tablets, ODEFSEY® 200 MG - 25 MG - 25 MG TABLETAS RECUBIERTASCategories: Vitamin B Complex, Cytochrome P-450 Substrates
  7. Drug

    AVXS-201

    go.drugbank.com/drugs/DB16997
    ApprovedWithdrawn

    Synonyms: AVXS-201
  8. Drug

    Vedolizumab

    go.drugbank.com/drugs/DB09033
    ApprovedInvestigational

    Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative … [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter.

    Products: ENTYVIO® 108 MG SOLUCIÓN INYECTABLE, ENTYVIO® (SUBCUTÁNEO) VEDOLIZUMAB 108 MG SOLUCIÓN INYECTABLE
  9. Drug

    Idarucizumab

    go.drugbank.com/drugs/DB09264
    Approved

    As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when given to patients at increased risk (elderly, chronic kidney disease … Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its

    Products: PRAXBİND 50 MG/ML ENJEKSİYONLUK/İNFÜZYONLUK ÇÖZELTİ, 2 ADET, PRAXBIND®
  10. Drug

    Carfilzomib

    go.drugbank.com/drugs/DB08889
    ApprovedInvestigational

    Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. … FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, P-glycoprotein inhibitorsProducts: Kyprolis 10 mg IV İnfüzyonluk Çözelti Hazırlamak İçin Toz, 1 ADET, ANPROTSOM ® 60 MG